Polymorphic forms α, β and γ of rifaximin

Details Polymorphic forms α, β and γ of rifaximin Polymorphic forms α, β and γ of rifaximin

2011-03-08

2011-03-08

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C540S456000

Reexamination Certificate

active

07902206

ABSTRACT:
Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

REFERENCES:
patent: 4341785 (1982-07-01), Marchi et al.
patent: 4557866 (1985-12-01), Cannata et al.
patent: 7045620 (2006-05-01), Viscomi et al.
patent: 2009/0028940 (2009-01-01), Jahagirdar et al.
patent: 2009/0082558 (2009-03-01), Kothakonda et al.
patent: 2009/0312357 (2009-12-01), Rao et al.
patent: 1215976 (1986-12-01), None
patent: 1218650 (1987-03-01), None
patent: 0161534 (1985-11-01), None
patent: 0 161 534 (1989-09-01), None
patent: 1698630 (2006-09-01), None
patent: 1557421 (2007-05-01), None
patent: 2011486 (2009-01-01), None
patent: MI2005A000345 (2005-03-01), None
patent: 2008/155728 (2008-12-01), None
patent: 2009/008005 (2009-01-01), None
patent: 2009/047801 (2009-04-01), None
patent: 2009/108730 (2009-09-01), None
Rossi, C. et al., “NMR Investigation of a New Semisynthetic Bioactive Compound,” Bulletin of Magnetic Resonance, 1996, vol. 18, No. 1-2, pp. 87-90.
Viscomi, G. et al., “Crystal Forms of Rifaximin and Their Effect on Pharmaceutical Properties,” CrystEngComm, 2008, 10, 1074-1081.
Italian Product Label for NORMIX (rifaximin), Apr. 23, 1985.
European Patent No. 1 557 421, Reply to the Communication pursuant to Article 96(2), May 2, 2006.
European Patent No. 1 557 421, Opposition Proceedings, “Notice of opposition to a European patent,” Feb. 11, 2008.
European Patent No. 1 557 421, Opposition Proceedings, Patentee response to Notice of Opposition, Sep. 10, 2008.
European Patent No. 1 557 421, Opposition Proceedings, Opinion of the Opposition Division, Jan. 19, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Patentee response to summons to attend oral proceedings, Apr. 22, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Opponent response to summons to attend oral proceedings, Apr. 29, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Patentee response to brief communication, May 29, 2009.
European Patent No. 1 557 421, Opposition Proceedings, European Patent Office Decision rejecting the opposition, Jul. 8, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Appellant Notice of Appeal, Sep. 18, 2009.
European Patent No. 1 557 421, Opposition Proceedings, Appellant Statement of Grounds for Appeal, Nov. 18, 2009.
Alvisi, V. et al., “Treatment of Secretory Diarrhoeas - A Double-Blind Trial of the Effectiveness of Rifaximin (L 105) and Neomycin,” Clinical Trials Journal, 1984, 21, No. 4, pp. 215-223.
Rodriguez-Spong, B. et al., “General Principles of Pharmaceutical Solid Polymorphism: a Supramolecular Perspective,” Advanced Drug Delivery Reviews, 56 (2004), 241-274.
Morris, K.R. et al., “Theoretical Approaches to Physical Transformations of Active Pharmaceutical Ingredients During Manufacturing Processes,” Advanced Drug Delivery Reviews, 48 (2001), 91-114.
Brufani, M. et al., “X-Ray Crystal Structure of 4-Deoxy-3′-bromopyrido[1,2′-1,2]imidazo[5,4-c]rifamycin S,” The Journal of Antibiotics, 37:12, 1623-1627 (Dec. 1984).
Soro, O. et al., “Selection of Rifampicin-Resistant Mycobacterium Tuberculosis Does Not Occur in the Presence of Low Concentrations of Rifaximin,” Clin Microbiol Infect, 1997, 3:147-151.
TicinumLab. Example 7, Patent EP 0 161 534, “Synthesis of 4-Deoxy-4′methyl-pyrido-[1′,2′:1,2]imidazo]5,4-c]ryfamicin SV.”.
TicinumLab. Example 9, Patent EP 0 161 534, “Synthesis of 4-Deoxy-4′methyl-pyrido-[1′,2′:1,2]imidazo]5,4-c]ryfamicin SV.”.
Department of Health and Human Services, Certificate of GMP Compliance of a Manufacturer, Nov. 16, 2007.
European Medicines Industry, ICH Topic Q6A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, pp. 1-32, 2000.
Henwood, S.Q. et al., “Solubility and Dissolution Properties of Generic Rifampicin Raw Materials,” Drug Development and Industrial Pharmacy, 26(4), 403-408 (2000).
Morris, K.R. “Polymorphism in Pharmaceutical Solids,” in “Structural Aspects of Hydrates and Sovates,” H.G. Brittain editor, Drugs and the Pharmaceutical Sciences, vol. 95, Chapter 4, pp. 125-181, 1999.
Rifaximin - Intrinsic Dissolution Experimental Data, Apr. 2009.
Bacchi, A. et al., “Sampling Rifamycin Conformational Variety by Cruising Through Crystal Forms: Implications for Polymorph Screening and for Biological Models,” New J. Chem., 2008, 32, 1725-1735.
Venturini, A.P. “Pharmacokinetics of L/105, a New Rifamycin, in Rats and Dogs, after Oral Administration,” Chemotherapy 29:1-3 (1983).
Pelizza, G. “Polymorphism of Rifampicin,” II Farmaco - Ed. Sc., vol. 32, No. 7, pp. 471-481, 1977.
Rao, R.N. et al., “O-Line 2D-LC-ESI/MS/MS Determination of Rifaximin in Rat Serum,” Biomed. Chromatogr. 2009, 1-6.
Descombe, J.J. et al., “Pharmacokinetic Study of Rifaximin After Oral Administration in Healthy Volunteers,” Int. J. Clin. Pharm. Res. XIV(2), 51-56 (1994).
Cellai, L. et al., “A Study of Structure-Activity Relationships in 4-Deoxypyrido[1′,2′-1,2] imidazo[5,4-c]rifamycin SV Derivatives by Electron Spectroscopy for Chemical Analysis and 1H NMR,” Molecular Pharmacology, 27:103-108, 1984.
European Patent No. 1 557 421, Opposition Proceedings, “Opponent Response to the Late Submissions of Patentee,” Jun. 11, 2009.
European Patent No. 1 557 421, Opposition Proceedings, “Patentee Response to Opponent Statement Setting Out the Grounds of Appeal,” Jun. 2, 2010.
Zach Systems SPA, “Synthesis of rifaximin obtained according to examples 7 and 9 reported in European Patent EP0161534,” May 13, 2010.
TicinumLab. Example 7. Patent EP 0 161 534, “Synthesis of 4-Deoxy-4-40 methyl-pyrido-[1′,2′:1,2]imidazo]5,4-c]ryfamicin SV.” (2009).
TicinumLab. Example 9. Patent EP 0 161 534, “Synthesis of 4-Deoxy-4-40 methyl-pyrido-[1′,2′:1,2]imidazo]5,4-c]ryfamicin SV.” (2009).

Affiliated with

Also associated with

Rating

Polymorphic forms α, β and γ of rifaximin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphic forms α, β and γ of rifaximin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic forms α, β and γ of rifaximin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2641188